In addition, attempts using gene therapy with CRISPR/Cas9 and adeno-associated vectors (AVV) have been made to restore NKG2D expression and glycosylation function, by correcting both CD8 and NK cells to combat infections rapidly and provide a long-term response by editing hematopoietic stem cells (HSPC) (49). This evidence concerns the gene KLRK1 and infection.